Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD
Cognition Therapeutics (Nasdaq: CGTX) has published research in Nature Scientific Reports demonstrating the potential of their drug candidate zervimesine (CT1812) in treating dry age-related macular degeneration (dry AMD).
The research comprised multiple studies, including analysis of cerebrospinal fluid from Alzheimer's disease clinical trials and collaborative in vitro research with the University of Southampton. The studies revealed that zervimesine treatment altered proteins and pathways associated with geographic atrophy and macular degeneration.
Laboratory tests showed that zervimesine could rescue impaired cellular processes in retinal pigment epithelial (RPE) cells, which are important for breaking down photoreceptor debris and maintaining sight. While the results support zervimesine's potential in treating dry AMD, the company will currently focus its financial resources on Alzheimer's disease and dementia with Lewy bodies.
Cognition Therapeutics (Nasdaq: CGTX) ha pubblicato una ricerca su Nature Scientific Reports che dimostra il potenziale del loro candidato farmaco zervimesine (CT1812) nel trattamento della degenerazione maculare secca legata all'età (dry AMD).
La ricerca comprendeva diversi studi, tra cui l'analisi del liquido cerebrospinale proveniente da trial clinici sulla malattia di Alzheimer e ricerche in vitro collaborative con l'Università di Southampton. Gli studi hanno rivelato che il trattamento con zervimesine ha alterato proteine e vie metaboliche associate all'atrofia geografica e alla degenerazione maculare.
I test di laboratorio hanno mostrato che zervimesine potrebbe recuperare processi cellulari compromessi nelle cellule epiteliali pigmentate retiniche (RPE), che sono importanti per la degradazione dei detriti dei fotorecettori e per il mantenimento della vista. Sebbene i risultati supportino il potenziale di zervimesine nel trattamento della dry AMD, l'azienda attualmente concentrerà le proprie risorse finanziarie sulla malattia di Alzheimer e sulla demenza con corpi di Lewy.
Cognition Therapeutics (Nasdaq: CGTX) ha publicado una investigación en Nature Scientific Reports que demuestra el potencial de su candidato a fármaco zervimesina (CT1812) en el tratamiento de la degeneración macular seca relacionada con la edad (dry AMD).
La investigación incluyó múltiples estudios, que abarcaron el análisis del líquido cefalorraquídeo de ensayos clínicos de la enfermedad de Alzheimer y una investigación in vitro colaborativa con la Universidad de Southampton. Los estudios revelaron que el tratamiento con zervimesina alteró proteínas y vías asociadas con la atrofia geográfica y la degeneración macular.
Las pruebas de laboratorio mostraron que zervimesina podría rescatar procesos celulares dañados en las células epiteliales pigmentarias retinianas (RPE), que son importantes para descomponer los desechos de los fotorreceptores y mantener la visión. Si bien los resultados respaldan el potencial de zervimesina en el tratamiento de la dry AMD, la empresa actualmente centrará sus recursos financieros en la enfermedad de Alzheimer y la demencia con cuerpos de Lewy.
Cognition Therapeutics (Nasdaq: CGTX)는 Nature Scientific Reports에 연구 결과를 발표하여 그들의 약물 후보인 zervimesine (CT1812)가 나이 관련 건성 황반 변성(dry AMD) 치료에 대한 잠재력을 보여주고 있습니다.
이 연구는 알츠하이머병 임상 시험에서의 뇌척수액 분석 및 사우샘프턴 대학교와의 협력 연구를 포함한 여러 연구로 구성되었습니다. 연구 결과는 zervimesine 치료가 지리적 위축 및 황반 변성과 관련된 단백질 및 경로를 변화시켰다는 것을 보여주었습니다.
실험실 테스트는 zervimesine이 망막 색소 상피(RPE) 세포에서 손상된 세포 과정을 회복할 수 있음을 보여주었습니다. 이 세포는 광수용체 잔여물을 분해하고 시력을 유지하는 데 중요합니다. 결과가 zervimesine의 건성 AMD 치료 가능성을 뒷받침하지만, 현재 회사는 알츠하이머병 및 루이체 치매에 재정 자원을 집중할 것입니다.
Cognition Therapeutics (Nasdaq: CGTX) a publié des recherches dans Nature Scientific Reports démontrant le potentiel de leur candidat médicament zervimesine (CT1812) dans le traitement de la dégénérescence maculaire sèche liée à l'âge (dry AMD).
La recherche comprenait plusieurs études, y compris l'analyse du liquide céphalorachidien provenant des essais cliniques sur la maladie d'Alzheimer et une recherche in vitro collaborative avec l'Université de Southampton. Les études ont révélé que le traitement par zervimesine a modifié des protéines et des voies associées à l'atrophie géographique et à la dégénérescence maculaire.
Les tests de laboratoire ont montré que zervimesine pouvait restaurer des processus cellulaires altérés dans les cellules épithéliales pigmentaires rétiniennes (RPE), qui sont importantes pour décomposer les débris des photorécepteurs et maintenir la vue. Bien que les résultats soutiennent le potentiel de zervimesine dans le traitement de la dry AMD, l'entreprise concentrera actuellement ses ressources financières sur la maladie d'Alzheimer et la démence à corps de Lewy.
Cognition Therapeutics (Nasdaq: CGTX) hat eine Forschung in Nature Scientific Reports veröffentlicht, die das Potenzial ihres Medikamentenkandidaten zervimesine (CT1812) zur Behandlung der trockenen altersbedingten Makuladegeneration (dry AMD) demonstriert.
Die Forschung umfasste mehrere Studien, darunter die Analyse von Gehirn-Rückenmarksflüssigkeit aus klinischen Studien zur Alzheimer-Krankheit und kollaborative In-vitro-Forschung mit der Universität Southampton. Die Studien zeigten, dass die Behandlung mit zervimesine Proteine und Wege beeinflusste, die mit geographischer Atrophie und Makuladegeneration verbunden sind.
Laboruntersuchungen zeigten, dass zervimesine beeinträchtigte Zellprozesse in den retinalen Pigmentepithelzellen (RPE) retten könnte, die wichtig für den Abbau von Photorezeptor-Resten und die Erhaltung des Sehens sind. Während die Ergebnisse das Potenzial von zervimesine zur Behandlung von trockener AMD unterstützen, wird das Unternehmen derzeit seine finanziellen Ressourcen auf die Alzheimer-Krankheit und die Lewy-Körper-Demenz konzentrieren.
- Published research validates zervimesine's potential in dry AMD treatment
- Successful laboratory demonstration of cellular function restoration
- Multiple studies confirm drug's impact on disease-relevant proteins
- Company not pursuing dry AMD indication despite positive results
- Resources being diverted from promising AMD program to focus on other indications
Insights
Cognition Therapeutics has published research in Nature Scientific Reports demonstrating the potential efficacy of zervimesine (CT1812) for treating dry age-related macular degeneration (dry AMD), a condition with treatment options affecting millions worldwide.
The multi-faceted research revealed two significant findings. First, analysis of cerebrospinal fluid from Alzheimer's patients treated with zervimesine showed alterations in proteins and pathways strongly associated with geographic atrophy and macular degeneration. Second, in collaboration with the University of Southampton, researchers demonstrated that zervimesine could rescue the function of retinal pigment epithelial (RPE) cells exposed to amyloid beta oligomers or oxidative stress - addressing a key pathological mechanism in dry AMD.
This research highlights the mechanistic overlap between neurodegenerative conditions like Alzheimer's and retinal diseases like dry AMD, particularly regarding amyloid-related pathology. The ability to potentially repurpose zervimesine across multiple indications could significantly enhance its commercial value proposition.
However, despite these promising preclinical results, Cognition has stated they will focus their current financial resources on Alzheimer's disease and dementia with Lewy bodies rather than dry AMD. This strategic decision likely reflects both the competitive landscape in ophthalmology and the company's resource constraints as a micro-cap biotech (
For investors, this publication demonstrates scientific validation of Cognition's platform while establishing potential future pipeline opportunities. The company appears to be building scientific credibility for zervimesine while pragmatically focusing near-term resources on their primary CNS indications where they may have competitive or strategic advantages.
Collaborators at the University of Southampton, UK and Cognition Scientists Show Rescue of Function in a Cell Model of Dry AMD
PURCHASE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing neurodegenerative disease candidates, (the “Company” or “Cognition”) announced the publication of a manuscript reviewing recent work supporting the potential of zervimesine (CT1812), a small molecule drug candidate to treat dry age-related macular degeneration (dry AMD). The Journal of Nature Scientific Reports has published the paper online: https://www.nature.com/articles/s41598-025-87921-9.
Several separate studies were conducted and are reported in this manuscript:
a) an analysis of cerebrospinal fluid (CSF) collected from participants of two Alzheimer’s disease clinical trials to identify the impact of zervimesine treatment on disease-relevant proteins;
b) a separate analysis of these CSF samples to identify pathways associated with dry AMD that were altered by treatment with zervimesine;
c) an in vitro study conducted in collaboration with researchers at the University of Southampton, UK to investigate zervimesine’s ability to rescue important cellular processes in a cell model of dry AMD.
Mary Hamby, Ph.D., Cognition Therapeutic's VP of research explained, “We analyzed CSF samples from studies of zervimesine in adults with mild-to-moderate Alzheimer’s disease. From this, we found that treatment with zervimesine altered proteins and pathways strongly associated with geographic atrophy and macular degeneration. These findings support the potential of zervimesine to impact pathways impaired in retinal diseases.”
Cognition Therapeutics also worked with Arjuna Ratnayaka, Ph.D. in the School of Clinical and Experimental Sciences at the University of Southampton to conduct an in vitro study showing the potential that a small molecule candidate may rescue cellular processes that are impaired in dry AMD.
“Retinal pigment epithelial (RPE) cells are responsible for breaking down the cellular debris generated by photoreceptors, which are specialized cells in the retina necessary for sight,” stated Dr. Ratnayaka. “The ability of RPE cells to carry out this function is essential for the health and survival of photoreceptors. We modelled this in the laboratory and showed that RPE cells’ capacity to break down photoreceptor outer segments (debris) was compromised when when the cells are exposed to amyloid beta oligomers or oxidative stress. However, the addition of zervimesine and other compounds from Cognition Therapeutics’ library normalized the function of RPE cells.”
The Company continues to believe that zervimesine has the potential to alter the biological processes that contribute to dry AMD. However, at this time, the Company intends to focus its current financial resources on Alzheimer’s disease and dementia with Lewy bodies.
About Zervimesine (CT1812)
Zervimesine (CT1812) is an investigational oral, once-daily pill being developed for the treatment of CNS diseases such as Alzheimer’s disease and dementia with Lewy bodies (DLB). While these diseases have different symptoms, both are associated with the buildup of certain proteins in the brain - Aβ and ɑ-synuclein. As these proteins bind to neurons, they can damage and ultimately destroy the neurons. This results in a progressive loss in a person’s ability to learn, recall memories, move efficiently, or communicate. These diseases progress relentlessly and ultimately result in death. If zervimesine can interrupt the toxic effects of these proteins, it may be able to slow progression of disease and improve the lives of those suffering from Alzheimer’s and DLB.
The USAN Council has adopted zervimesine as the United States Adopted Name (USAN) for CT1812.
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc., is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system. We are currently investigating our lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease, including the ongoing START study (NCT05531656) in early Alzheimer’s disease. We believe zervimesine can regulate pathways that are impaired in these diseases though its interaction with the sigma-2 receptor, a mechanism that is functionally distinct from other approaches for the treatment of degenerative diseases. More about Cognition Therapeutics and our pipeline can be found at https://cogrx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our expected runway, product candidates, including zervimesine (CT1812), and any expected or implied benefits or results, including that initial clinical results observed with respect to zervimesine will be replicated in later trials and our clinical development plans, the timing of any regulatory interactions and submissions, and expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; impacts of ongoing global and region conflicts on our business, supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Global Market; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities Exchange Commission and are available at www.sec.gov. These risks are not exhaustive, and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
| Contact Information: Cognition Therapeutics, Inc. info@cogrx.com | Casey McDonald (media) Tiberend Strategic Advisors, Inc. cmcdonald@tiberend.com | Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com |
This press release was published by a CLEAR® Verified individual.
FAQ
What did the latest research reveal about CGTX's zervimesine for dry AMD treatment?
How did CGTX's zervimesine perform in the University of Southampton collaboration study?
Where was CGTX's zervimesine research published in February 2025?
What are CGTX's current development priorities for zervimesine?
